March 9, 2017 / 5:59 AM / 5 months ago

South Africa's Aspen posts 6 pct rise in H1 profit

1 Min Read

JOHANNESBURG, March 9 (Reuters) - South African drugmaker Aspen Pharmacare Holdings Ltd reported a 6 percent rise in first-half profit on Thursday, helped by the results of a recently acquired portfolio of medicines from AstraZeneca .

Aspen, the biggest generic drugmaker in the southern hemisphere, said normalised headline earnings per share rose to 692 cents in the six months ended December 2016, from 656 cents a year earlier.

Headline EPS is the main profit measure in South Africa and strips out certain one-off items.

Aspen said the results were largely boosted by the $770 million acquisition of marketing rights to a portfolio of anaesthetics from AstraZeneca in September last year. (Reporting by Tiisetso Motsoeneng; Editing by Subhranshu Sahu)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below